Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Neoplasms 3Chemotherapy-induced Neutropenia 3Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1

Interventions

pegfilgrastim 5NPI 2358 3balugrastim 2Granulocyte Colony-Stimulating Factor 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Chemotherapy-induced Neutropenia × NPI 2358 × Clear all
NCT03102606 2024-08-29

Protective-1

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
105 enrolled 16 charts

Chemotherapy-induced Neutropenia

NCT04345900 2024-05-16

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
55 enrolled 21 charts

Chemotherapy-induced Neutropenia

NCT04227990 2020-01-18

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
115 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡